▶주메뉴 바로가기

▶본문 바로가기

The Korea Herald
검색폼

THE INVESTOR
March 29, 2024

Bio

Celltrion’s Remsima overtakes Remicade in Europe

  • PUBLISHED :March 28, 2018 - 16:46
  • UPDATED :March 28, 2018 - 16:48
  • 폰트작게
  • 폰트크게
  • facebook
  • sms
  • print

[THE INVESTOR] Two biosimilars developed by Celltrion -- Remsima and Truxima -- have further increased their market share in Europe, putting more pressure on the companies that produce original drugs.

Celltrion Healthcare said on March 28 that Remsima, copy of Johnson & Johnson’s autoimmune disease therapy Remicade, has taken 52 percent market share away from the US pharma giant as of end-2017, based on data from health care information provider IQVIA.

“In Europe, the brand value of Celltrion has been boosted thanks to Remsima which was launched three years ago. The second biosimilar Truxima is also getting a foothold as a drug which physicians and patients can trust,” Celltrion Healthcare said in a statement. 




Truxima, knockoff of Roch’s Rituxan, which is being sold in 12 countries in Europe since its first UK launch in April last year, is joining Remsima to build market presence.

Its market share in five major European countries -- UK, Germany, France, Spain and Italy -- stood at 16 percent. The Netherlands and UK, in particular, showed strong uptake of the biosimilar version with market share of 58 percent and 43 percent, respectively.

The company said it expects that Herzuma, its version of Roche’s Herceptin, which will hit some EU countries by June, will follow suit.

By Park Han-na (hnpark@heraldcorp.com)

EDITOR'S PICKS